Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pain and Therapy
Published in: Pain and Therapy 3/2022

Open Access 05-07-2022 | Tramadol | Study Protocol

DANTE Study: The First Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Arm Group Study Evaluating the Analgesic Efficacy and Safety of Dexketoprofen TrometAmol aNd Tramadol Hydrochloride Oral FixEd Dose Combination on Moderate to Severe Acute Pain in Patients with Acute Low Back Pain—Rationale and Design

Authors: Giustino Varrassi, Magdi Hanna, Stefano Coaccioli, Meto Suada, Serge Perrot

Published in: Pain and Therapy | Issue 3/2022

Login to get access

Abstract

Introduction

Despite a wide range of treatment approaches and the availability of treatment recommendations or guidelines, no consensus on the most effective pharmacological therapy of low back pain (LBP) has been reached yet. Therefore, additional clinical evidence, particularly if built upon a rigorous clinical trial design, an evidence-based medication choice, and broader inclusion criteria better acknowledging the heterogeneity and intrinsic variability of LBP is needed. The DANTE study has been designed to comprehensively assess the analgesic efficacy and tolerability of dexketoprofen/tramadol (DKP/TRAM) 75/25 mg in a large cohort of patients with moderate to severe acute LBP.

Methods

The DANTE study is a phase IV, multicenter, randomized, double-blind, double-dummy parallel group, placebo, and active controlled study. The DANTE study encompasses a single-dose phase (day 1, t0–t8h) and a multiple-dose phase (from t8h to 8 h after intake of last dose at day 5). The DANTE study population includes patients naïve to LBP or patients with previous history of LBP experiencing a new episode of moderate to severe intensity with or without radiculopathy. The clinical phase of the DANTE study started in September 2020 and the anticipated completion date is April 2022.

Planned Outcomes

The primary endpoint is the time to first achieve a numeric rating scale-pain intensity (NRS-PI) score of < 4 or a pain intensity reduction ≥ 30% from drug intake up to 8 h after the first dose (t8h). Secondary objectives aim are: (1) to evaluate the analgesic efficacy of TRAM/DKP 75/25 mg versus TRAM 100 mg after the first dose; (2) to evaluate the analgesic efficacy of TRAM/DKP 75/25 mg versus TRAM 100 mg after the multiple doses (from t8h until day 5, multiple dose); and (3) to assess the safety and tolerability of the TRAM/DKP 75/25 mg fixed combination after single and multiple doses.

DANTE Study Registration

EudraCT number: 2019-003656-37.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Wu A, March L, Zheng X, et al. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Ann Transl Med. 2020;8:299.PubMedPubMedCentralCrossRef
4.
5.
Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to pay attention. Lancet. 2018;10137:2356–67.CrossRef
6.
Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018;27:2791–803.PubMedCrossRef
7.
Hooten WM, Cohen SP. Evaluation and treatment of low back pain: a clinically focused review for primary care specialists. Mayo Clin Proc. 2015;90:1699–718.PubMedCrossRef
8.
Selim AJ, Ren XS, Fincke G, et al. The importance of radiating leg pain in assessing health outcomes among patients with low back pain. Results from the Veterans Health Study. Spine (Phila Pa 1976) 1998;23:470–74.
9.
Parker SL, Godil SS, Mendenhall SK, et al. Two-year comprehensive medical management of degenerative lumbar spine disease (lumbar spondylolisthesis, stenosis, or disc herniation): a value analysis of cost, pain, disability, and quality of life. J Neurosurg Spine. 2014;21:143–9.PubMedCrossRef
10.
11.
Nguyen C, Lefèvre-Colau M, Kennedy DJ, Schneider BJ, Rannou F. Low back pain. Lancet. 2018;392:2547.PubMedCrossRef
12.
Allegri M, Montella S, Salici F, et al. Mechanism of low back pain: a guide for diagnosis and therapy. F1000Research. 2016; 5(F1000 Faculty Rev):1530.
13.
da Silva T, Mills K, Brown BT, et al. Risk of recurrence of low back pain: a systematic review. J Orthop Sports Phys Ther. 2017;47:305–13.PubMedCrossRef
14.
Itz CJ, Geurts JW, van Kleef M, Nelemans P. Clinical course of non-specific low back pain: a systematic review of prospective cohort studies set in primary care. Eur J Pain. 2013;17(1):5–15.PubMedCrossRef
15.
Migliorini F, Maffulli N, Eschweiler J, et al. The pharmacological management of chronic lower back pain. Expert Opin Pharmacother. 2021;22(1):109–19.PubMedCrossRef
16.
Morlion B. Pharmacotherapy of low back pain: targeting nociceptive and neuropathic pain components. CMRO. 2011;27:11–33.
17.
Qaseem A, Wilt T, McLean RM, et al. Noninvasive treatments for acute, subacute, and chronic low back pain: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2017;166:514–30.PubMedCrossRef
18.
O’Connell NE, Chook CE, Wand BM, Ward SP. Clinical guidelines for low back pain: a critical review of consensus and inconsistencies across three major guidelines. Best Pract Res Clin Rheumatol. 2016;30:968–80.PubMedCrossRef
19.
Di Iorio D, Henley E, Doughty A. A survey of primary care physician practice patterns and adherence to acute low back problem guidelines. Arch Fam Med. 2000;9:1015–21.PubMedCrossRef
20.
Schers H, Braspenning J, Drijver R, Wensing M, Grol R. Low back pain in general practice: reported management and reasons for not adhering to the guidelines in The Netherlands. Br J Gen Pract. 2000;50:640–4.PubMedPubMedCentral
21.
Ivanova J, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW. Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care. Spine J. 2011;11:622–32.PubMedCrossRef
22.
Amonkar SJ, Dunbar AM. Do patients and general practitioners have different perceptions about the management of simple mechanical back pain? Int Musculoskelet Med. 2011;33:3–7.CrossRef
23.
Ramanathan SA, Hibbert PD, Maher CG, et al. CareTrack: toward appropriate care for low back pain. Spine (Phila Pa 1976). 2017;42:E802–9.
24.
Varrassi G, Moretti B, Pace MC, Evangelista P, Iolascon G. Common clinical practice from low back pain treatment: a modified Delphi study. Pain Ther. 2021;10:589–604.PubMedPubMedCentralCrossRef
25.
Enke O, New HA, New CH, et al. Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis. CMAJ. 2018;190:E786-93.PubMedPubMedCentralCrossRef
26.
Ferreira GE, MacLachlan AJ, Chung-Wei CL, et al. Efficacy and safety of antidepressants for the treatment of back pain and osteoarthritis: systematic review and meta-analysis. BMJ. 2021;372:n80.
27.
Varrassi G, Alon E, Bagnasco M, Lanata L, Mayoral- Rojals V, Paladini A, et al. Towards an effective and safe treatment of inflammatory pain: a Delphi-guided expert consensus. Adv Ther. 2019;36:2618–37.PubMedPubMedCentralCrossRef
28.
Williams CM, Maher CG, Latimer J, et al. Efficacy of paracetamol for acute low-back pain: a double-blind, randomised controlled trial. Lancet. 2014;384: 961586.
29.
Roelofs PD, Deyo RA, Koes BW, et al. Non-steroidal anti-inflammatory drugs for low back pain. Cochrane Database Syst Rev. 2008;23:CD000396.
30.
Shaheed CA, Ferreira G, Dmitritchenko A, et al. The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews. Med J Aust. 2021;214:324–31.PubMedCrossRef
31.
Saragiotto BT, Machado GC, Ferreira ML, Pinheiro MB, Abdel Shaheed C, Maher CG. Paracetamol for low back pain. Cochrane Database System Rev. 2016(6):CD012230.
32.
Babej DR, Freytag S, Eckmeyer J, et al. Parenteral dipyrone versus diclofenac and placebo in patients with acute lumbago or sciatic pain: randomized observer blind multicenter study. Int J Clin Pharmacol Ther. 1994;32:204–9.
33.
Amlie E, Weber H, Holme I. Treatment of acute low-back pain with piroxicam: results of a double-blind placebo-controlled trial. Spine (Phila Pa 1976). 1987;12:473–6.
34.
Friedman BW, Dym AA, Davitt M, et al. Naproxen with cyclobenzaprine, oxycodone/acetaminophen, or placebo for treating acute low back pain: a randomized clinical trial. JAMA. 2015;314:1572–80.PubMedCrossRef
35.
Varrassi G, Hanna M, Macheras G, et al. Multimodal analgesia in moderate-to-severe pain: a role for a new fixed combination of dexketoprofen and tramadol. Curr Med Res Opin. 2017;33:1165–73.PubMedCrossRef
36.
Hanna M, Montero A, Perrot S, Varrassi G. Tramadol/dexketoprofen analgesic efficacy compared with tramadol/paracetamol in moderate to severe postoperative acute pain: subgroup analysis of a randomized, double-blind, parallel group trial—DAVID study. Pain Ther. 2021;10:485–503.PubMedPubMedCentralCrossRef
37.
Mathieson S, Kasch R, Maher CG, et al. Combination drug therapy for the management of low back pain and sciatica; systematic review and meta-analysis. J Pain. 2019;20:1–15.PubMedCrossRef
38.
Varrassi G, Yeam CT, Rekatsina M, Pergolizzi JV, Zis P, Paladini A. The expanding role of the COX inhibitor/opioid receptor agonist combination in the management of pain. Drugs. 2020;80:1443–53.PubMedPubMedCentralCrossRef
39.
Moore RA, Gay-Escoda C, Figueiredo R, et al. Dexketoprofen/tramadol: randomised double-blind trial and confirmation of empirical theory of combination analgesics in acute pain. J Headache Pain. 2015;16:541.PubMedCrossRef
40.
Moore RA, McQuay HJ, Tomaszewski J, et al. Dexketoprofen/tramadol 25 mg/75 mg: randomised double-blind trial in moderate-to-severe acute pain after abdominal hysterectomy. BMC Anesthesiol. 2016;16:9.PubMedPubMedCentralCrossRef
41.
McQuay HJ, Moore RA, Berta A, et al. Randomized clinical trial of dexketoprofen/tramadol 25mg/75mg in moderate-to-severe pain after total hip arthroplasty. Br J Anaesth. 2016;116:269–76.PubMedPubMedCentralCrossRef
42.
Gay-Escoda C, Hanna M, Montero A, et al. Tramadol/dexketoprofen (TRAM/DKP) compared with tramadol/paracetamol in moderate to severe acute pain: results of a randomised, double-blind, placebo and active-controlled, parallel group trial in the impacted third molar extraction pain model (DAVID study). BMJ Open. 2019;9:e023715.PubMedPubMedCentralCrossRef
43.
Montero Matamala A, Bertolotti M, Contini MP, et al. Tramadol hydrochloride 75 mg/dexketoprofen 25 mg oral fixed-dose combination in moderate-to-severe acute pain: sustained analgesic effect over a 56-h period in the postoperative setting. Drugs Today (Barc). 2017;53:339–47.CrossRef
44.
Meloncelli S, Divizia M, Germani G. Efficacy and tolerability of orally administered tramadol/dexketoprofen fixed- dose combination compared to diclofenac/thiocolchicoside in acute low back pain: experience from an Italian, single-centre, observational study. Curr Med Res Opin. 2020;36:1687–93.PubMedCrossRef
45.
Perna A, Ricciardi L, Barone G, et al. Medical management of acute non-specific low back pain: comparison of different medical treatments, one center’s retrospective analysis. J Biol Regul Homeost Agents. 2018;32:121–9.PubMed
46.
Spitzer WO. Scientific approach to the assessment and measurement of activity-related spinal disorders: a monograph for clinicians—report of the Quebec Task Force on spinal disorders. Spine. 1987;12(Suppl):S1–59.
47.
Roland MO, Morris RW. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low back pain. Spine 1983; 8:141–4.
48.
Roland MO, Morris RW. A study of the natural history of back pain. Part II: development of guidelines for trials of treatment in primary care. Spine 1983;8: 145–50.
49.
Atkinson MJ, Sinha A, Hass SL, et al. Validation of a general measure of treatment satisfaction, the treatment satisfaction questionnaire for medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcome. 2004;2:1–13.CrossRef
50.
Lasko B, Jevitt RJ, Rainsford KD, Bouchard S, Rozova A, Robertson S. Extended-release tramadol/paracetamol in moderate-to-severe pain: a randomized, placebo-controlled study in patients with acute low back pain. Curr Med Res Opin. 2021;28:847–57.CrossRef
51.
52.
53.
Carvalho C, Caetano JM, Cunha L, et al. Open-label placebo treatment in chronic low back pain: a randomized controlled trial. Pain. 2016;157:2766–72.PubMedPubMedCentralCrossRef
54.
55.
Panella L, Rinonapoli G, Coaccioli S. Where should analgesia lead to? Quality of life and functional recovery with tapentadol. J Pain Res. 2019;12:1561–7.PubMedPubMedCentralCrossRef
56.
Van Boekel RLM, Vissers KCP, van der Sande R, Bronkhorst E, Lerou JGC, Steegers MAH, et al. Moving beyond pain scores: multidimensional pain assessment is essential for adequate pain management after surgery. PLoS One. 2017;12:e0177345.PubMedPubMedCentralCrossRef
57.
Deyo RA, Battie M, Beurskens AJ, et al. Outcome measures for low back pain research: a proposal for standardized use. Spine (Phila Pa 1976) 1998;23:2003–13.
58.
Smeets R, Koke A, Lin CW, Ferreira M, Demoulin C. Measures of function in low back pain/disorders: Low Back Pain Rating Scale (LBPRS), Oswestry Disability Index (ODI), Progressive Isoinertial Lifting Evaluation (PILE), Quebec Back Pain Disability Scale (QBPDS), and Roland-Morris Disability Questionnaire (RDQ). Arthritis Care Res. 2011;63(Suppl S11):S158–73.
59.
Turner JA, Fulton-Kehoe D, Franklin G, Wickizer TM, Wu R. Comparison of the Roland–Morris Disability Questionnaire and generic health status measures: a population-based study of workers' compensation back injury claimants. Spine (Phila Pa 1976). 2003;28810:1061–7.
60.
Varrassi G, Coaccioli S, De-Andres J, et al. Expert consensus on clinical use of an orally administered dexketoprofen plus tramadol fixed- dose combination in moderate-to-severe acute pain: a Delphi study. Adv Ther. 2019;36:3174–85.PubMedPubMedCentralCrossRef
Metadata
Title
DANTE Study: The First Randomized, Double-Blind, Placebo and Active-Controlled, Parallel Arm Group Study Evaluating the Analgesic Efficacy and Safety of Dexketoprofen TrometAmol aNd Tramadol Hydrochloride Oral FixEd Dose Combination on Moderate to Severe Acute Pain in Patients with Acute Low Back Pain—Rationale and Design
Authors
Giustino Varrassi
Magdi Hanna
Stefano Coaccioli
Meto Suada
Serge Perrot
Publication date
05-07-2022
Publisher
Springer Healthcare
Published in
Pain and Therapy / Issue 3/2022
Print ISSN: 2193-8237
Electronic ISSN: 2193-651X
DOI
https://doi.org/10.1007/s40122-022-00407-8

Other articles of this Issue 3/2022

Pain and Therapy 3/2022 Go to the issue

Original Research

Comparison of Patient-Controlled Caudal Epidural Analgesia and Patient-Controlled Intravenous Analgesia After Perianal Surgery: A Randomized Controlled Trial

Original Research

Bilateral Erector Spinae Plane Block for Quality of Recovery Following Posterior Lumbar Interbody Fusion: A Randomized Controlled Trial

Original Research

External Concurrent Occipital and Trigeminal Neurostimulation Relieves Migraine Headache: A Prospective, Randomized, Double-Blind, Sham-Controlled Trial

Original Research

Food-Specific IgG4 Antibody-Guided Exclusion Diet Improves Conditions of Patients with Chronic Pain

Original Research

Differences in Brain Activity Between Dopa-Responsive and -Unresponsive Pain in Parkinson’s Disease

Original Research

A Survey of the Incidence of Constipation in Patients with Chronic Non-cancer Pain Using Opioid Analgesics in Japan
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits